These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 1665286

  • 1. CGS 22745: a selective orally active inhibitor of 5-lipoxygenase.
    Kimble E, Kowalski T, White D, Raychauduri A, Pastor G, Chertock H, Lee W, Neale R, Hamdan A, Wasley J.
    Agents Actions; 1991 Sep; 34(1-2):125-8. PubMed ID: 1665286
    [Abstract] [Full Text] [Related]

  • 2. Characterization of CGS 8515 as a selective 5-lipoxygenase inhibitor using in vitro and in vivo models.
    Ku EC, Raychaudhuri A, Ghai G, Kimble EF, Lee WH, Colombo C, Dotson R, Oglesby TD, Wasley JW.
    Biochim Biophys Acta; 1988 Apr 15; 959(3):332-42. PubMed ID: 2833314
    [Abstract] [Full Text] [Related]

  • 3. Selective inhibition of arachidonate 5-lipoxygenase by novel acetohydroxamic acids: biochemical assessment in vitro and ex vivo.
    Tateson JE, Randall RW, Reynolds CH, Jackson WP, Bhattacherjee P, Salmon JA, Garland LG.
    Br J Pharmacol; 1988 Jun 15; 94(2):528-39. PubMed ID: 2840160
    [Abstract] [Full Text] [Related]

  • 4. Pre-clinical pharmacology of ICI D2138, a potent orally-active non-redox inhibitor of 5-lipoxygenase.
    McMillan RM, Spruce KE, Crawley GC, Walker ER, Foster SJ.
    Br J Pharmacol; 1992 Dec 15; 107(4):1042-7. PubMed ID: 1334748
    [Abstract] [Full Text] [Related]

  • 5. WY-50,295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity.
    Grimes D, Sturm RJ, Marinari LR, Carlson RP, Berkenkopf JW, Musser JH, Kreft AF, Weichman BM.
    Eur J Pharmacol; 1993 May 19; 236(2):217-28. PubMed ID: 8391458
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Effects of sulfasalazine and a sulfasalazine analogue on the formation of lipoxygenase and cyclooxygenase products.
    Tornhamre S, Edenius C, Smedegård G, Sjöquist B, Lindgren JA.
    Eur J Pharmacol; 1989 Oct 10; 169(2-3):225-34. PubMed ID: 2572437
    [Abstract] [Full Text] [Related]

  • 8. Tepoxalin: a dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile.
    Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, Rosenthale ME, Capetola RJ.
    J Pharmacol Exp Ther; 1994 Dec 10; 271(3):1399-408. PubMed ID: 7996452
    [Abstract] [Full Text] [Related]

  • 9. 1-[4-[3-[4-[bis(4-fluorophenyl)hydroxymethyl]-1- piperidinyl]propoxy]-3-methoxyphenyl]ethanone(AHR-5333): a selective human blood neutrophil 5-lipoxygenase inhibitor.
    Graff G, Anderson LA.
    Prostaglandins; 1989 Oct 10; 38(4):473-96. PubMed ID: 2554366
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Inhibition of LTB4 biosynthesis in situ by CGS 23885, a potent 5-lipoxygenase inhibitor, correlates with its pleural fluid concentrations in an experimentally induced rat pleurisy model.
    Raychaudhuri A, Chertock H, Chovan J, Jones LS, Kimble EF, Kowalski TJ, Peppard J, White DH, Satoh Y, Roland D.
    Naunyn Schmiedebergs Arch Pharmacol; 1997 Apr 10; 355(4):470-4. PubMed ID: 9109363
    [Abstract] [Full Text] [Related]

  • 13. 2-substituted indazolinones: orally active and selective 5-lipoxygenase inhibitors with anti-inflammatory activity.
    Foster SJ, Bruneau P, Walker ER, McMillan RM.
    Br J Pharmacol; 1990 Jan 10; 99(1):113-8. PubMed ID: 2110012
    [Abstract] [Full Text] [Related]

  • 14. Characterization of leukotriene B4 synthesis in canine polymorphonuclear leukocytes.
    Amalsadvala TM, Vaughn DM.
    Prostaglandins Leukot Essent Fatty Acids; 1992 Apr 10; 45(4):283-8. PubMed ID: 1318548
    [Abstract] [Full Text] [Related]

  • 15. 5-lipoxygenase inhibitory activity of zileuton.
    Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW.
    J Pharmacol Exp Ther; 1991 Mar 10; 256(3):929-37. PubMed ID: 1848634
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2.
    Tries S, Neupert W, Laufer S.
    Inflamm Res; 2002 Mar 10; 51(3):135-43. PubMed ID: 12005204
    [Abstract] [Full Text] [Related]

  • 18. Involvement of leukotriene B4 in zymosan-induced rat pleurisy: inhibition of leukocyte infiltration by the 5-lipoxygenase inhibitor T-0757.
    Kikuchi M, Tsuzurahara K, Naito K.
    Biol Pharm Bull; 1995 Sep 10; 18(9):1302-4. PubMed ID: 8845830
    [Abstract] [Full Text] [Related]

  • 19. Substituted chromenes as potent, orally active 5-lipoxygenase inhibitors.
    Satoh Y, Stanton JL, Hutchison AJ, Libby AH, Kowalski TJ, Lee WH, White DH, Kimble EF.
    J Med Chem; 1993 Nov 12; 36(23):3580-94. PubMed ID: 8246226
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of leukotriene formation in human leukocytes by halothane.
    Yamaoka A, Sumimoto H, Takeshige K, Itoh T, Isobe R, Yoshitake J, Minakami S.
    Biochim Biophys Acta; 1987 Apr 24; 918(3):284-92. PubMed ID: 3032266
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.